BAIT
DOT1L
DOT1, KMT4
DOT1-like histone H3K79 methyltransferase
GO Process (3)
GO Function (3)
GO Component (0)
Gene Ontology Biological Process
Gene Ontology Molecular Function
Homo sapiens
PREY
HSP90B1
ECGP, GP96, GRP94, HEL-S-125m, HEL35, TRA1
heat shock protein 90kDa beta (Grp94), member 1
GO Process (13)
GO Function (6)
GO Component (13)
Gene Ontology Biological Process
- ER-associated ubiquitin-dependent protein catabolic process [IMP]
- actin rod assembly [IDA]
- activation of signaling protein activity involved in unfolded protein response [TAS]
- cellular protein metabolic process [TAS]
- cellular response to ATP [IDA]
- endoplasmic reticulum unfolded protein response [TAS]
- innate immune response [TAS]
- negative regulation of apoptotic process [IMP, TAS]
- protein transport [NAS]
- regulation of phosphoprotein phosphatase activity [IDA]
- response to hypoxia [IDA]
- sequestering of calcium ion [NAS]
- toll-like receptor signaling pathway [TAS]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
- cytosol [IDA]
- endocytic vesicle lumen [TAS]
- endoplasmic reticulum [IDA, TAS]
- endoplasmic reticulum lumen [IDA, TAS]
- endoplasmic reticulum membrane [IDA]
- extracellular matrix [IDA]
- extracellular region [TAS]
- extracellular vesicular exosome [IDA]
- focal adhesion [IDA]
- membrane [IDA]
- midbody [IDA]
- nucleus [IDA]
- perinuclear region of cytoplasm [IDA]
Homo sapiens
Affinity Capture-MS
An interaction is inferred when a bait protein is affinity captured from cell extracts by either polyclonal antibody or epitope tag and the associated interaction partner is identified by mass spectrometric methods.
Publication
Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Targeting vulnerabilities of cancer cells by inhibiting key regulators of cell proliferation or survival represents a promising way to overcome resistance to current therapies. In breast cancer (BC), resistance to endocrine therapy results from constitutively active or aberrant estrogen receptor alpha (ER?) signaling to the genome. Targeting components of the ER? pathway in these tumors represents, therefore, a rational way ... [more]
Breast Cancer Res Dec. 18, 2021; 24(1);52 [Pubmed: 35850772]
Throughput
- Low Throughput
Curated By
- BioGRID